A

Metabolic Surgery Research

Procedure volume is falling while case mix grows more complex

Melissa V. Wills; Xinlei Zhu; Doua Elamin; Ricard Corcelles; Matthew Kroh; Jerry Dang; Andrew Strong; Salvador Navarrete | Obesity Surgery, 2026 | Source ‚Üó

This MBSAQIP analysis examined 1,006,270 bariatric procedures performed from 2020 through 2024. The central signal is a 23% drop in volume from the 2022 peak, even as conversions and medically complex patients took up a larger share of practice. Short-term safety did not deteriorate across the study window, which makes the volume decline harder to dismiss as a quality response. The paper reads as a workforce and access warning, not just an annual-volume report.

For bariatric surgeons, the trend should prompt questions about referral flow, insurance policy, GLP-1 displacement, and patient confidence after the pandemic years. Lower volume can threaten team experience, hospital investment, and trainee exposure while the cases that remain may demand more advanced judgment. Programs should watch their own conversion mix, revision burden, severity markers, and time-to-operation alongside national trends. If access is narrowing while complexity rises, the specialty needs to say that clearly.

Class 4 obesity outcomes reinforce the need for procedure-specific counseling

Sonmez Ocak; Omer Faruk Buk; Can Akgun; Mehmet Alperen Avci; Ahmet Can Sari; Mustafa Safa Uyanik | Obesity Surgery, 2026 | Source ‚Üó

This retrospective cohort compared outcomes after bariatric surgery in 570 patients with class 2-3 obesity and class 4 obesity. Patients with class 4 obesity achieved durable weight loss, but the magnitude of response differed by operation. Within that higher-BMI group, one-anastomosis gastric bypass and Roux-en-Y gastric bypass outperformed sleeve gastrectomy on weight-loss endpoints. The tally also flags higher mortality, so the efficacy signal needs to be read with perioperative risk in view.

The practical message is not that every patient with class 4 obesity needs bypass. It is that procedure selection should be explicit about expected weight loss, comorbidity burden, operative risk, nutritional consequences, and follow-up capacity. Sleeve remains a reasonable operation for many patients, but counseling in very high BMI ranges should not pretend that all procedures are metabolically interchangeable. Surgeons should pair ambition on weight loss with honest perioperative planning.

Most adolescents meet textbook outcome benchmarks after MBS

Michael T. Olson; Mark Shacker; Justine O. Chinn; Brian D. Layton; Janey S. A. Pratt | Journal of the American College of Surgeons, 2026 | Source ‚Üó

This MBSAQIP adolescent cohort study evaluated textbook outcomes after metabolic and bariatric surgery. The authors found that 90.8% of adolescent cases met the composite benchmark, with higher rates after sleeve gastrectomy than Roux-en-Y gastric bypass. The analysis also identified persistent race and ethnicity disparities. That combination gives the field both reassurance and unfinished work.

For surgeons caring for adolescents, textbook outcomes are useful because they combine several perioperative safety and quality events into one patient-centered benchmark. High overall performance supports appropriately selected adolescent MBS rather than delaying care until adulthood by default. The disparity signal matters just as much as the headline rate. Programs should examine access, preoperative optimization, procedure selection, follow-up, and family support by race and ethnicity rather than assuming strong aggregate outcomes mean equity.

Metabolic syndrome and COPD may predict greater one-year weight loss

Urszula Stepaniak et al. | Journal of Obesity, 2026 | Source ‚Üó

Stepaniak and colleagues analyzed 601 adults treated at a high-volume Polish bariatric center between 2009 and 2021 with documented weight at one year. Most patients underwent sleeve gastrectomy, and 91.0% had weight loss at follow-up. Obesity-related disease was common: hypertension was present in 71.2%, metabolic syndrome in 59.7%, diabetes in 33.6%, and COPD in 3.5%. In unadjusted comparisons, hypertension, metabolic syndrome, and COPD were associated with greater total weight loss, while osteoarthritis and GERD were associated with lower weight loss.

The adjusted signal narrowed. After controlling for age, sex, and baseline BMI, metabolic syndrome and COPD remained independently associated with greater one-year total weight loss. Metabolic syndrome was associated with about 2.4 percentage points greater weight loss from admission weight, while COPD was associated with about 6.5 percentage points greater loss, with similar findings when maximum recorded weight was used. The authors caution that this retrospective, single-center dataset captured only 41.4% of eligible records with one-year follow-up, had limited COPD numbers, and cannot prove causality. The practical takeaway is not that comorbid disease guarantees better response. It is that preoperative phenotype, disease burden, follow-up intensity, and adherence may interact with weight-loss outcomes in ways worth studying.

B

Science of Obesity Metabolism

Obesity guidance is moving beyond BMI alone

Nature Reviews Endocrinology authors / Springer Nature | Nature Reviews Endocrinology, 2026 | DOI source

This Nature Reviews Endocrinology synthesis reviews contemporary obesity guidelines and the fieldand a gradual shift away from BMI-only diagnosis. The authors emphasize staging that incorporates adiposity distribution, body composition, organ dysfunction, functional impairment, and complications. Because the article is a guideline synthesis rather than a trial, its value is in organizing a more clinically accurate framework. The message fits what bariatric teams already see: two patients with the same BMI can have very different disease.

For surgeons, better staging can improve referral timing, procedure counseling, and communication with payers. BMI remains useful for eligibility and population measurement, but it is a blunt tool for individual risk. Central adiposity, diabetes severity, sleep apnea, liver disease, mobility, sarcopenia, and quality of life often explain urgency better than BMI class alone. The specialty should support staging systems that recognize obesity as a disease with anatomy, function, and organ injury, not just weight.

Food deserts enter the recurrence conversation after colon cancer surgery

Claire Wild; Jincong Q. Freeman; Armaan Jamal; Jasmin Tiro; Kayla Councell; Benjamin D. Shogan | Annals of Surgery, 2026 | DOI source

This Annals of Surgery single-institution retrospective cohort studied 166 patients with stage I-III colon cancer after curative resection. Residence in a USDA-defined food desert was independently associated with earlier recurrence and worse recurrence-free survival. This is colorectal oncology rather than bariatric surgery, and the design cannot prove that food access caused recurrence. The finding belongs in MBS Digest because the same food environment shapes obesity, metabolic disease, recovery, and surveillance.

Bariatric surgeons should read the paper as a social-determinants prompt. Food access affects protein quality, produce intake, diabetes control, postoperative eating patterns, and the ability to follow nutrition advice. If geography and food availability influence cancer recovery, they almost certainly influence obesity treatment adherence and long-term metabolic health. Programs can respond practically by screening for food insecurity, connecting patients to local resources, and avoiding counseling that assumes every patient can shop the same way.

A patient-facing GLP-1 explainer raises real surgical questions

University Hospitals / Leena Khaitan, MD, MPH | University Hospitals, 2026 | Source ‚Üó

This University Hospitals educational article explains how GLP-1 medications slow gastric emptying, increase satiety, and produce gastrointestinal symptoms. It is not original research, but it captures the questions patients are bringing to clinic: nausea, constipation, retained gastric contents, and concern about gastroparesis. The clinical content is familiar, yet its patient-facing framing is useful. It shows how medication physiology is becoming common vocabulary outside specialist offices.

For bariatric surgeons, GLP-1 physiology matters before, during, and after operative care. Patients may present for endoscopy, anesthesia, or surgery while taking drugs that affect gastric emptying and oral intake. Teams need clear pre-procedure medication instructions, symptom screening, hydration planning, and nutrition counseling. The larger lesson is that medication history now includes mechanism and tolerability, not just the drug name and dose.

Oral orforglipron data extend the GLP-1 discussion to older adults

Deborah B. Horn; Alpana P. Shukla; Haocheng Huang; Elvis Twum; Sheryl Elaine Allen; Sanja Giljanovic Kis | Obesity Pillars, 2026 | DOI source

This Obesity Pillars post hoc subgroup analysis pooled older-adult data from the Phase 3 ATTAIN-1 and ATTAIN-2 trials of once-daily oral orforglipron. Among 616 randomized participants aged 65 years or older, 613 received treatment. At 72 weeks, the highest orforglipron dose was associated with mean weight reductions of 13.0% in ATTAIN-1 and 12.2% in ATTAIN-2, compared with 1.6% and 2.3% with placebo, respectively. Gastrointestinal adverse events were the most common and were generally mild to moderate.

The paper is useful because older adults are often under-discussed in obesity pharmacotherapy, but it should be read with the right cautions. This was a post hoc subgroup analysis funded by Eli Lilly, several authors were company employees, and the trials were not designed around geriatric endpoints such as sarcopenia, bone density, nutritional deficits, frailty, or falls. The authors also note CYP3A4/polypharmacy considerations. For bariatric teams, the source paper supports careful counseling rather than reflex enthusiasm: oral GLP-1 options may reduce injection barriers, but older patients still need individualized risk, nutrition, function, and medication-review planning.

C

Metabolic Innovation and Technology

Deep learning CT segmentation questions what BMI misses after MBS

Emily P. Rabinovich; Jayasuriya Senthilvelan; Claire K. Foley; Andrew Gillikin; Chengli Shen; Arun Krishnaraj; Thomas H. Shin | Journal of the American College of Surgeons, 2026 | Source ‚Üó

This proof-of-concept study used deep learning CT segmentation to measure body-composition change after metabolic and bariatric surgery. The authors found that BMI only weakly reflected changes in visceral fat and muscle remodeling. The cohort is small, and imaging-derived metrics need prospective validation before routine clinical use. Still, the work points toward a more precise view of postoperative metabolic change.

Surgeons already know that BMI can hide meaningful differences in visceral adiposity, lean mass, and functional reserve. Automated CT segmentation could eventually help identify sarcopenic obesity, visceral-fat response, and patients who need more intensive protein or resistance-training support. The barrier is not only algorithm performance. Any tool must prove that measuring body composition changes management and improves outcomes enough to justify cost, radiation context, and workflow burden.

Ottava authorization adds pressure to the bariatric robotics market

Apelo Consulting | Apelo Consulting, 2026 | Source ‚Üó

Apelo Consulting analyzes FDA de novo authorization of Johnson & Johnson's Ottava robotic surgery system. The report notes broad general-surgery clearance that includes bariatric and gastrointestinal procedures, along with an integrated-table architecture that may differentiate the platform. This is consulting analysis rather than independent clinical evidence. Its value is as a market signal in a robotics category that is becoming less single-vendor by the year.

For bariatric surgeons and hospital leaders, a new platform should trigger disciplined evaluation rather than brand enthusiasm. Programs will need comparative data on docking, stapling workflow, ergonomics, conversion, OR time, leak and bleeding outcomes, cost, training, and service reliability. Competition may improve purchasing leverage and innovation, but only if platforms prove value in real bariatric cases. Authorization opens the door; outcomes determine whether teams walk through it.

Robotic RYGB database results show benefits with tradeoffs

Matthew L. Brengman; Pranav H. Waghmare; Isaac F. Shih | Journal of Robotic Surgery, 2026 | Source ‚Üó

This retrospective Premier Healthcare Database study compared robotic-assisted and laparoscopic Roux-en-Y gastric bypass. Robotic RYGB was associated with lower odds of open conversion, ICU admission, transfusion, length-of-stay category, and 30-day reencounters. The same analysis found longer operating-room time and more bowel obstruction. Propensity matching helps, but residual selection bias remains possible in a database study.

The paper gives bariatric surgeons a more balanced robotics discussion than either marketing copy or blanket skepticism. Lower conversion and resource-use signals matter, especially in complex cases, but longer OR time and bowel obstruction cannot be waved away. Programs considering robotic expansion should track their own outcomes against these domains rather than relying on vendor or national averages. The right question is where robotics adds measurable value in a specific practice.

EndoZip IDE enrollment moves automated ESG closer to a U.S. evidence test

Nitinotes Ltd. / PRNewswire | PRNewswire, 2026 | Source ‚Üó

Nitinotes announced the first Orlando Health procedures in the U.S. EASE IDE trial of EndoZip. The device is an automated suturing system intended to standardize endoscopic sleeve gastroplasty for obesity treatment. This is a company press release, and the product remains investigational in the United States. The news is best read as a trial-initiation milestone, not an efficacy claim.

Bariatric surgeons and endoscopists should follow the EASE trial because standardization is one of the hard problems in endoscopic obesity therapy. If automation reduces technical variability, it could affect training, reproducibility, procedure time, and broader adoption. That remains an if until U.S. IDE data report weight loss, durability, adverse events, and revision or rescue pathways. For now, the responsible stance is interest with restraint.

D

Metabolic Marketplace

Hims & Hers FTC dispute puts DTC obesity platforms under a brighter light

Hims & Hers Health / Business Wire; FTC/CNBC/Reuters coverage | Business Wire, 2026 | Source ‚Üó

Hims & Hers responded to an FTC lawsuit involving privacy, billing, and subscription practices. The company denies the allegations, and the tally notes corroborating coverage from CNBC, Reuters, and FTC search snippets when the Business Wire extraction was limited. For this newsletter, the story functions as a marketplace and regulatory signal rather than clinical evidence. Direct-to-consumer obesity care now sits squarely inside consumer protection, health data, and subscription-policy scrutiny.

Bariatric surgeons may not manage DTC platforms, but their patients use them. That means medication histories can include compounded products, telehealth prescriptions, subscription friction, privacy concerns, and interrupted access. Practices should ask where patients obtained anti-obesity medications and whether billing or continuity problems affected adherence. The broader lesson is that obesity care delivery models will be judged on trust, transparency, and clinical safety, not only convenience.

Employer GLP-1 coverage remains stuck between risk and cost

Mike Hollan and Susan Thomas | Pharmaceutical Executive, 2026 | Source ‚Üó

This Pharmaceutical Executive Q and A discusses employer-benefit coverage gaps for GLP-1 medications. The interview argues that diabetes-versus-weight-loss formulary buckets miss people with cardiometabolic risk who may benefit from treatment. Because the source is an interview with a PBM executive, it should be read as a market-access perspective rather than outcomes research. Even so, it captures the pressure employers face as demand, price, and risk stratification collide.

For bariatric surgeons, coverage design affects who reaches surgery and what treatment sequence patients have tried first. Some patients will receive medication only after diabetes develops; others will lose coverage when the indication is obesity alone. That can create stop-start pharmacotherapy, frustration, and delayed referral. Surgical programs should document payer barriers and help frame obesity treatment as risk reduction, not cosmetic spending.

Viking VK2735 timeline keeps the obesity pipeline moving

Viking Therapeutics / PRNewswire | Viking Therapeutics Investor Relations, 2026 | Source ‚Üó

Viking Therapeutics reported second-quarter 2026 results and obesity-program updates for VK2735. The company said Phase 3 VANQUISH trials for the subcutaneous formulation are fully enrolled, oral Phase 3 initiation is expected in the fourth quarter of 2026, and maintenance-dosing data are expected in the third quarter. This is an investor update, not independent clinical evidence. Its relevance is pipeline timing in a fast-moving obesity pharmacotherapy market.

Bariatric surgeons should track these pipeline signals because medication availability changes patient expectations long before approvals are finalized. New injectable and oral options may alter referral timing, bridge therapy, preoperative weight loss, and postoperative recurrence management. They may also intensify payer restrictions if prices remain high. The clinical posture should be informed but careful: promising company timelines are not the same as peer-reviewed outcomes or real-world access.